13.1 Basic Epidemiology & Outbreak Measures

Basic Epidemiology & Outbreak Measures

Epidemiology provides the quantitative foundation for clinical decision-making. For the DHA GP exam, a general practitioner must master the concepts of disease frequency, diagnostic test performance, and outbreak measures. These metrics guide not only individual patient care but also public health interventions, such as screening programs and outbreak containment in the UAE.

Incidence vs. Prevalence

Disease frequency is measured primarily in two ways: incidence and prevalence. While they are related, they capture different dimensions of disease burden.

• Incidence measures the rate at which new cases of a disease develop in a population at risk over a specified period. It acts as a measure of the risk of developing a disease.
  • Cumulative Incidence (Incidence Proportion): The number of new cases divided by the total population at risk at the beginning of the time period. This assumes all individuals are followed for the entire period.
  • Incidence Rate (Incidence Density): The number of new cases divided by the total person-time of observation. This accounts for individuals entering or leaving the study at different times.
• Prevalence measures the proportion of a population that has a disease at a specific point in time (point prevalence) or over a specified period (period prevalence). It is a measure of the total disease burden, including both new and pre-existing cases.

The mathematical relationship between prevalence ($P$), incidence ($I$), and the average duration of the disease ($D$) is expressed as:

$P \approx I \times D$

This relationship holds true when the population is stable and prevalence is low (less than 10%). This formula explains how clinical interventions affect these parameters:

1. Prolonging Survival: A new therapeutic agent that prevents death from a chronic disease (e.g., antiretroviral therapy for HIV) but does not cure it will increase the average duration ($D$). This causes prevalence to increase, while the incidence remains unchanged.
2. Developing a Vaccine: A highly effective vaccine prevents new infections, which decreases incidence. Consequently, the prevalence will decrease over time.
3. Introducing a Rapid Cure: A drug that rapidly cures a disease (e.g., direct-acting antivirals for Hepatitis C) will dramatically decrease the duration ($D$), leading to a decrease in prevalence, even if the incidence initially remains constant.

---

Diagnostic Testing and the 2x2 Contingency Table

Evaluating the validity of diagnostic and screening tests is a key competency. All calculations are based on a standard 2x2 contingency table comparing the test results against a gold standard diagnosis:

Using this table, we define four critical parameters:

• Sensitivity (True Positive Rate): The probability that the test is positive in patients who actually have the disease. $\text{Sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}}$ Clinical Utility: High-sensitivity tests are used for screening (e.g., HIV ELISA). A highly sensitive test has very few false negatives, meaning a negative result effectively rules out the disease (SNOUT).
• Specificity (True Negative Rate): The probability that the test is negative in patients who do not have the disease. $\text{Specificity} = \frac{\text{TN}}{\text{TN} + \text{FP}}$ Clinical Utility: High-specificity tests are used for confirmation (e.g., Western blot or PCR). A highly specific test has very few false positives, meaning a positive result effectively rules in the disease (SPIN).
• Positive Predictive Value (PPV): The probability that a patient with a positive test result actually has the disease. $\text{PPV} = \frac{\text{TP}}{\text{TP} + \text{FP}}$
• Negative Predictive Value (NPV): The probability that a patient with a negative test result is truly free of the disease. $\text{NPV} = \frac{\text{TN}}{\text{TN} + \text{FN}}$

The Critical Impact of Prevalence on PPV and NPV

While sensitivity and specificity are intrinsic properties of a diagnostic test and do not change with disease prevalence, PPV and NPV are extrinsic properties that vary directly with the prevalence of the disease in the tested population:

• When Prevalence Increases:
  • PPV increases: There are more true positives and fewer false positives in the tested population.
  • NPV decreases: There are more false negatives and fewer true negatives, lowering the confidence in a negative result.
• When Prevalence Decreases:
  • PPV decreases: Even a highly specific test will yield a high proportion of false positives relative to true positives when the disease is rare.
  • NPV increases: The vast majority of the population is healthy, so a negative test is highly likely to be correct.

For example, testing a patient for coronary artery disease in a specialized cardiology clinic (high prevalence) yields a much higher PPV than testing an asymptomatic patient in a routine primary care screening (low prevalence).

---

Outbreak and Risk Measures

During infectious disease outbreaks (such as foodborne illness or viral epidemics), physicians must calculate measures of association to identify the source and risk of transmission.

Attack Rate

The attack rate is the biostatistical term for the cumulative incidence of infection during an epidemic. It is expressed as a percentage:

$\text{Attack Rate} = \frac{\text{Number of new cases of disease}}{\text{Total population at risk at start of outbreak}} \times 100$

For instance, if 150 people attend a wedding and 30 develop gastroenteritis, the attack rate is $30/150 = 20%$.

Relative Risk (RR)

Relative Risk compares the risk of developing a disease in an exposed group to the risk in an unexposed group. It is the primary measure of association used in prospective cohort studies.

$\text{Relative Risk (RR)} = \frac{\text{Incidence of disease in exposed group}}{\text{Incidence of disease in unexposed group}} = \frac{A / (A + B)}{C / (C + D)}$

• $RR > 1$: Exposure is associated with increased risk of disease (harmful exposure).
• $RR < 1$: Exposure is associated with decreased risk of disease (protective exposure, e.g., vaccination).
• $RR = 1$: No association between exposure and disease.

Odds Ratio (OR)

Odds Ratio compares the odds of exposure among cases (diseased) to the odds of exposure among controls (non-diseased). It is the primary measure of association in case-control studies.

$\text{Odds Ratio (OR)} = \frac{\text{Odds of exposure in cases}}{\text{Odds of exposure in controls}} = \frac{A / C}{B / D} = \frac{A \times D}{B \times C}$

The Rare Disease Assumption

In clinical research, case-control studies are often used because they are faster and cheaper than cohort studies. However, they yield an Odds Ratio rather than a Relative Risk. The rare disease assumption states that OR closely approximates RR when the prevalence of the disease in the population is low (typically < 5%).

Why does this happen mathematically? If the disease is rare, the number of diseased individuals ($A$ and $C$) is very small compared to the healthy individuals ($B$ and $D$). Therefore, $A + B \approx B$ and $C + D \approx D$. Substituting these into the RR formula makes it mathematically equivalent to the OR formula:

$\text{RR} = \frac{A / (A + B)}{C / (C + D)} \approx \frac{A / B}{C / D} = \frac{A \times D}{B \times C} = \text{OR}$